Summary

Despite advancements in antivirals and antibiotics, significant challenges persist, notably antimicrobial resistance and the scarcity of broad-spectrum antiviral treatments, necessitating alternative approaches for infectious diseases.
These issues result in a global burden of approximately 1.52 billion annual hospitalizations and 2.5 million deaths each year worldwide.

Affirma Biotech is a startup company founded in 2022, leading the AIRE-INT consortium focused on respiratory infections in vulnerable populations.
The company has secured notable funding, including a €1.75 million round to advance its novel broad-spectrum anti-infectives.

The leadership team features diverse expertise, with board members possessing backgrounds in chemical engineering, biology, and economics.
Affirma Biotech has received support and certification from bodies including the Ministry of Science and Innovation, co-financed by the European Union.

Title

Innovative Medical Diagnostic Solutions | Affirma Biotech

Description

Affirma Biotech develops new orally available immunotherapeutic drugs for the treatment of severe infections and cancer

Keywords

biotech, infections, immune, broad, host, therapies, patients, burden, hospitalizations, deaths, solution, team, news, contact, drugs, influenza, spectrum

Downstreams

linkedin.com

NS Lookup

A 185.66.41.141

Dates

Created 2026-09-19

Updated 2026-09-29

Summarized 2026-10-01